Oral estramustine phosphate and oral etoposide for the treatment of hormone‐refractory prostate cancer
Author:
Affiliation:
1. Department of Urology, National Shikoku Cancer Center Hospital, Matsuyama, Ehime, Japan
Publisher
Wiley
Subject
Urology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1442-2042.2000.00183.x
Reference18 articles.
1. Treatment of Advanced Prostatic Carcinoma with Estramustine Phosphate (Estracyt®)
2. Treatment of stage D hormone‐resistant carcinoma of the prostate with estramustine phosphate.;Benson RC;J. Urol.,1979
3. Estramustine Phosphate Versus Placebo as Second Line Treatment After Orchiectomy in Patients With Metastatic Prostate Cancer: Daproca Study 9002
4. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.;Seidmen AD;J. Urol.,1992
5. Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Review: Cooperative group trials — Southwest Oncology Group (SWOG) innovations in advanced prostate cancer;Therapeutic Advances in Medical Oncology;2009-08-18
2. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model;Cancer Chemotherapy and Pharmacology;2006-06-07
3. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate;Cancer;2006
4. Prospective Study of Estramustine Phosphate for Hormone Refractory Prostate Cancer Patients following Androgen Deprivation Therapy;Urologia Internationalis;2005
5. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up;Urologic Oncology: Seminars and Original Investigations;2005-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3